ATE427103T1 - Orale verabreichung von adenosin analogen - Google Patents
Orale verabreichung von adenosin analogenInfo
- Publication number
- ATE427103T1 ATE427103T1 AT99960184T AT99960184T ATE427103T1 AT E427103 T1 ATE427103 T1 AT E427103T1 AT 99960184 T AT99960184 T AT 99960184T AT 99960184 T AT99960184 T AT 99960184T AT E427103 T1 ATE427103 T1 AT E427103T1
- Authority
- AT
- Austria
- Prior art keywords
- composition
- oral administration
- dosage form
- disclosed
- adenosine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/185,909 US6174873B1 (en) | 1998-11-04 | 1998-11-04 | Oral administration of adenosine analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE427103T1 true ATE427103T1 (de) | 2009-04-15 |
Family
ID=22682923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99960184T ATE427103T1 (de) | 1998-11-04 | 1999-11-01 | Orale verabreichung von adenosin analogen |
Country Status (13)
Country | Link |
---|---|
US (1) | US6174873B1 (de) |
EP (1) | EP1126828B1 (de) |
JP (2) | JP5523647B2 (de) |
AT (1) | ATE427103T1 (de) |
AU (1) | AU774055B2 (de) |
CA (1) | CA2347913C (de) |
DE (1) | DE69940674D1 (de) |
DK (1) | DK1126828T3 (de) |
ES (1) | ES2322724T3 (de) |
IL (2) | IL142801A0 (de) |
MX (1) | MXPA01004547A (de) |
PT (1) | PT1126828E (de) |
WO (1) | WO2000025758A1 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL136283A (en) | 1997-12-11 | 2006-10-31 | Bayer Schering Pharma Ag | Method for producing fludarabin phosphate |
EP1047692B1 (de) | 1998-01-14 | 2004-07-21 | The Uab Research Foundation | Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren |
US6673827B1 (en) | 1999-06-29 | 2004-01-06 | The Uab Research Foundation | Methods of treating fungal infections with inhibitors of NAD synthetase enzyme |
US6861448B2 (en) * | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
ATE324888T1 (de) * | 1999-06-14 | 2006-06-15 | Cancer Rec Tech Ltd | Krebstherapie |
AU6234000A (en) * | 1999-07-22 | 2001-02-13 | Supergen, Inc. | Methods for treating autoimmune diseases |
AUPR018900A0 (en) * | 2000-09-18 | 2000-10-12 | Fh Faulding Pty Limited | Pamidronate solution |
WO2002009700A1 (en) * | 2000-07-28 | 2002-02-07 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
ATE476968T1 (de) * | 2000-09-06 | 2010-08-15 | Mitsubishi Tanabe Pharma Corp | Granulat-zubereitungen zur oralen verabreichung |
PL360910A1 (en) * | 2000-09-18 | 2004-09-20 | F H Faulding & Co Limited | Diphosphonate solutions |
US7629329B2 (en) | 2001-06-04 | 2009-12-08 | Tsi Health Sciences, Inc. | Method for increasing muscle mass and strength through administration of adenosine triphosphate |
EP1429728A1 (de) * | 2001-08-29 | 2004-06-23 | SRL Technologies, Inc. | Zubereitungen mit verzögerter freisetzung |
GB0121285D0 (en) * | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
WO2003028712A2 (en) * | 2001-09-28 | 2003-04-10 | Universite Libre De Bruxelles | Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases |
US7037900B2 (en) * | 2001-10-12 | 2006-05-02 | Supergen, Inc. | Composition and method for treating graft-versus-host disease |
DE10164510A1 (de) * | 2001-12-20 | 2003-07-10 | Schering Ag | Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes |
US20030124178A1 (en) * | 2001-12-28 | 2003-07-03 | Haley Jeffrey T. | Soft, adherent, soluble oral patch |
US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
ES2309294T3 (es) * | 2002-02-01 | 2008-12-16 | Pfizer Products Inc. | Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferecncia de ester de colesterilo. |
GB2386836B (en) * | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
EP1542531A4 (de) * | 2002-05-24 | 2011-01-05 | Sicor Inc | WûSSRIGE FLUDARABINPHOSPHATZUSAMMENSETZUNG |
US20080220107A1 (en) * | 2002-09-03 | 2008-09-11 | Pharmacure Health Care Ab | Nasal spray apparatus |
GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
ITMI20022748A1 (it) * | 2002-12-23 | 2004-06-24 | Eurand Int | Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione. |
PL1608344T3 (pl) * | 2003-03-28 | 2011-01-31 | Ares Trading Sa | Doustne formulacje kladrybiny |
US20050118262A1 (en) * | 2003-09-17 | 2005-06-02 | Jack Aurora | Controlled release formulation |
GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
SG144146A1 (en) * | 2004-03-05 | 2008-07-29 | Cambridge Biotechnology Ltd | Adenosine receptor agonists |
US20050265955A1 (en) * | 2004-05-28 | 2005-12-01 | Mallinckrodt Inc. | Sustained release preparations |
WO2007023302A1 (en) * | 2005-08-26 | 2007-03-01 | Antisoma Plc | Combinations comprising dmxaa for the treatment of cancer |
US20070092559A1 (en) * | 2005-10-24 | 2007-04-26 | Jinghua Yuan | Liquid dosage forms having enteric properties of delayed and then sustained release |
DE102006006532B4 (de) | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmazeutische Zubereitung |
WO2007145191A1 (ja) * | 2006-06-13 | 2007-12-21 | Nippon Shinyaku Co., Ltd. | 被覆錠剤 |
US8845627B2 (en) | 2008-08-22 | 2014-09-30 | Boston Scientific Scimed, Inc. | Regulating pressure to lower temperature in a cryotherapy balloon catheter |
WO2010133629A1 (en) * | 2009-05-19 | 2010-11-25 | Grindeks, A Joint Stock Company | Stable pharmaceutical composition of fludarabine phosphate |
EP2428201A1 (de) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Orale Verabreichung von Nukleosidmonophosphaten |
WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
US8313774B1 (en) | 2012-06-26 | 2012-11-20 | Magnifica Inc. | Oral solid composition |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA7467B (en) * | 1973-01-16 | 1974-11-27 | J Voorhees | Compositions and treatment of proliferative skin diseases with b2 agonists |
US3923785A (en) | 1974-04-22 | 1975-12-02 | Parke Davis & Co | (R)-3-(2-deoxy-{62 -D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo{8 4,5-d{9 {8 1,3{9 diazepin-8-ol |
US3952741A (en) * | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
US4163839A (en) | 1977-12-09 | 1979-08-07 | Zaidan Hojin Biselbutsu Kagaku Kenkyu Kai | Isocoformycin and a process for the production thereof |
JPS57209225A (en) * | 1981-06-18 | 1982-12-22 | Yamasa Shoyu Co Ltd | Antitumor activity intensifier |
JPS57209226A (en) * | 1981-06-18 | 1982-12-22 | Yamasa Shoyu Co Ltd | Antitumor activity intensifier |
US5087618A (en) | 1982-05-18 | 1992-02-11 | University Of Florida | Redox carriers for brain-specific drug delivery |
JPS5920219A (ja) * | 1982-07-26 | 1984-02-01 | Shin Etsu Chem Co Ltd | 腸溶性コ−テイング製剤の製造方法 |
JPS5951223A (ja) * | 1982-09-17 | 1984-03-24 | Sumitomo Chem Co Ltd | 製剤組成物 |
US4713372A (en) | 1984-03-16 | 1987-12-15 | Warner-Lambert Company | 2-chloropentostatin compound having adenosine diaminase inhibitory activity |
US5254539A (en) * | 1985-08-26 | 1993-10-19 | U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health | Method of treating HIV with 2',3'-dideoxyinosine |
US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
US4912092A (en) | 1986-03-27 | 1990-03-27 | The Regents Of The University Of California | Methods for increasing extracellular adenosine and for stabilizing mast cells |
US5459256A (en) | 1987-04-17 | 1995-10-17 | The Government Of The United States Of America As Represented By The Department Of Health And Human Services | Lipophilic, aminohydrolase-activated prodrugs |
US5143661A (en) | 1987-05-26 | 1992-09-01 | American Cyanamid Company | Silicone-hardened pharmaceutical microcapsules |
US5000886A (en) | 1987-05-26 | 1991-03-19 | American Cyanamid Company | Silicone-hardened pharmaceutical microcapsules and process of making the same |
JPS649932A (en) * | 1987-07-01 | 1989-01-13 | Toyo Capsel Kk | Soft capsule preparation using newly combined component as the base |
US5521162A (en) | 1987-08-26 | 1996-05-28 | Merrell Pharmaceuticals Inc. | Aristeromycin analogues of 4',5'-didehydro-5'-fluoro-adenosine and methods of treating neoplastic and viral disease conditions |
US5132291A (en) | 1989-01-24 | 1992-07-21 | Gensia Pharmaceuticals, Inc. | Antivirals and methods for increasing the antiviral activity of azt |
JPH04501857A (ja) * | 1989-05-15 | 1992-04-02 | アメリカ合衆国 | 肝炎の治療方法 |
US5561136A (en) | 1990-12-13 | 1996-10-01 | Merrell Pharmaceuticals Inc. | Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent |
HU9202318D0 (en) * | 1991-07-22 | 1992-10-28 | Bristol Myers Squibb Co | Method for preparing medical preparatives containing didesoxi-purine nucleoside |
US5518730A (en) | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
JPH06316524A (ja) * | 1992-09-11 | 1994-11-15 | Naoyuki Inoue | 抗エイズウイルス剤 |
US5633274A (en) * | 1993-02-18 | 1997-05-27 | President And Fellows Of Harvard College | Cancer treatments |
US5366960A (en) | 1993-08-26 | 1994-11-22 | Warner-Lambert Company | Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol |
US5635156A (en) | 1993-09-13 | 1997-06-03 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
US5663155A (en) | 1994-11-30 | 1997-09-02 | The University Hospital | Compositions for the treatment of parasitic infections |
US5679648A (en) | 1994-11-30 | 1997-10-21 | The University Hospital | Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides |
JPH09100226A (ja) * | 1995-10-03 | 1997-04-15 | Sumitomo Pharmaceut Co Ltd | 腸溶・徐放性コーティング製剤の製法 |
AU6771198A (en) * | 1997-03-24 | 1998-10-20 | Glaxo Group Limited | Method for treating b-cell tumors with ara-g nucleoside derivatives |
US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
US8616566B2 (en) * | 2010-12-14 | 2013-12-31 | Hendrickson Usa, L.L.C. | Head plate for vehicle axle |
-
1998
- 1998-11-04 US US09/185,909 patent/US6174873B1/en not_active Expired - Lifetime
-
1999
- 1999-11-01 MX MXPA01004547A patent/MXPA01004547A/es active IP Right Grant
- 1999-11-01 CA CA2347913A patent/CA2347913C/en not_active Expired - Fee Related
- 1999-11-01 WO PCT/US1999/025676 patent/WO2000025758A1/en active IP Right Grant
- 1999-11-01 ES ES99960184T patent/ES2322724T3/es not_active Expired - Lifetime
- 1999-11-01 DK DK99960184T patent/DK1126828T3/da active
- 1999-11-01 JP JP2000579200A patent/JP5523647B2/ja not_active Expired - Fee Related
- 1999-11-01 IL IL14280199A patent/IL142801A0/xx active IP Right Grant
- 1999-11-01 AT AT99960184T patent/ATE427103T1/de not_active IP Right Cessation
- 1999-11-01 PT PT99960184T patent/PT1126828E/pt unknown
- 1999-11-01 DE DE69940674T patent/DE69940674D1/de not_active Expired - Lifetime
- 1999-11-01 AU AU17110/00A patent/AU774055B2/en not_active Ceased
- 1999-11-01 EP EP99960184A patent/EP1126828B1/de not_active Expired - Lifetime
-
2001
- 2001-04-24 IL IL142801A patent/IL142801A/en not_active IP Right Cessation
-
2010
- 2010-12-24 JP JP2010287707A patent/JP5580726B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
PT1126828E (pt) | 2009-05-25 |
AU1711000A (en) | 2000-05-22 |
MXPA01004547A (es) | 2003-07-21 |
DK1126828T3 (da) | 2009-06-15 |
JP2011057712A (ja) | 2011-03-24 |
JP5580726B2 (ja) | 2014-08-27 |
ES2322724T3 (es) | 2009-06-25 |
EP1126828A1 (de) | 2001-08-29 |
CA2347913C (en) | 2010-09-14 |
JP5523647B2 (ja) | 2014-06-18 |
DE69940674D1 (de) | 2009-05-14 |
AU774055B2 (en) | 2004-06-17 |
JP2002528487A (ja) | 2002-09-03 |
IL142801A (en) | 2006-04-10 |
CA2347913A1 (en) | 2000-05-11 |
US6174873B1 (en) | 2001-01-16 |
EP1126828B1 (de) | 2009-04-01 |
IL142801A0 (en) | 2002-03-10 |
WO2000025758A1 (en) | 2000-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE427103T1 (de) | Orale verabreichung von adenosin analogen | |
DE69940769D1 (de) | Orale flüssige zusammensetzungen | |
SE9301171D0 (sv) | Pharmaceutical composition containing lipophilic drugs | |
DE69318503T2 (de) | Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung | |
IL80149A (en) | Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases | |
NO20100302L (no) | Sammensetninger som inneholder organiske forbindelser | |
UA32512C2 (uk) | Похідні ксантину, спосіб їх одержання, та фармацевтична композиція | |
DE60019334D1 (de) | Antivirale arznei | |
BR0108435A (pt) | Formulação e uso de entecavir de baixa dose | |
MY101784A (en) | Novel pharmacological compounds | |
ATE202931T1 (de) | Taxanderivate enthaltende arzneizubereitungen | |
DE69033970D1 (de) | Huperzin a analoge verbindungen | |
ES2062610T3 (es) | Compuesto diarilico anti-ateroesclerotico. | |
SE8702563D0 (sv) | Pharmaceutical compositions | |
ATE215817T1 (de) | Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis | |
ATE60713T1 (de) | Pharmazeutische zusammensetzung aus guar-gummi und anderen antiacida zum schutz der oeso-gastro- duodenalen schleimhaut. | |
DE3583765D1 (de) | Hydantoinderivate und diese enthaltende pharmazeutische zusammensetzungen. | |
DK0773782T3 (da) | Terpenderivater (sarcodictyiner) anvendelse som antitumormidler | |
DK1144420T3 (da) | Sulfaterede phosphatidylinositoler, fremgangsmåde til fremstilling heraf og anvendelser heraf | |
YU81101A (sh) | Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija | |
ATE82128T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von krebs. | |
ES8303915A1 (es) | "procedimiento para la preparacion de comprimidos a base del antibiotico fosfomicina". | |
SE8704049D0 (sv) | Novel pharmacological compounds | |
ATE14837T1 (de) | Pharmazeutische zusammensetzungen. | |
MY102368A (en) | Solid sustained-release composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |